Clearside Biomedical Inc. | Mutual Funds
Mutual Funds that own Clearside Biomedical Inc.
Vanguard Total Stock Market Index Fund
608,323
1.9%
0
0%
07/31/2018
iShares Russell 2000 ETF
585,220
1.83%
-312
0.01%
09/06/2018
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
567,266
1.77%
67,266
0.18%
12/31/2017
Hartford Healthcare Fund
404,387
1.26%
-7,413
0.17%
07/31/2018
Vanguard Extended Market Index Fund
386,626
1.21%
0
0%
07/31/2018
iShares Russell 2000 Growth ETF
273,813
0.86%
0
0.02%
09/06/2018
Fidelity Select Biotechnology Portfolio
199,529
0.62%
0
0.02%
07/31/2018
Fidelity Spartan Extended Market Index Fund
128,137
0.4%
0
0%
07/31/2018
United Global Healthcare Fund
110,899
0.35%
22,494
0.19%
12/31/2017
Bridgeway Ultra Small Company Market Fund
99,200
0.31%
0
0.16%
12/31/2017
| Address |
900 North Point parkway
Alpharetta Georgia 30005
United States
|
|
Employees
|
- |
| Website |
http://www.clearsidebio.com |
| Updated |
07/08/2019 |
| Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. |
